2017
p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis
Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis. Journal Of Investigative Dermatology 2017, 137: 2187-2196. PMID: 28599981, PMCID: PMC6342201, DOI: 10.1016/j.jid.2016.12.033.Peer-Reviewed Original ResearchConceptsProtein synthesisRibosomal S6 kinase (RSK) familyPatient-derived melanoma cell linesDifferential protein expressionReverse phase protein arrayPhase protein arrayTranslation complexesKinase familyBI-D1870RSK inhibitorsMelanoma cell linesProtein arraysCell proliferationInhibitor treatmentProtein expressionCell linesNew targetsHuman melanoma patientsBRAF inhibitor vemurafenibAttenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas
Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodi N. Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. Melanoma Research 2017, 27: 85-96. PMID: 27997431, PMCID: PMC5812886, DOI: 10.1097/cmr.0000000000000315.Peer-Reviewed Original ResearchConceptsS-adenosyl methionineMelanoma cell linesEpigenetic featuresCell linesInactive chromatin regionsGenome-wide increaseUniversal methyl group donorMethyl group donorChromatin regionsCancer epigenomeEpigenetic modificationsEpigenetic abnormalitiesCytosine residuesMelanoma cell growthEpigenome modulationMalignant melanomaCell growthCovalent changesGroup donorSubcytotoxic levelsChemical substratesMelanoma cellsCutaneous malignant melanomaDose-dependent increaseResidues
2016
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell & Melanoma Research 2016, 29: 590-597. PMID: 27287723, PMCID: PMC5331933, DOI: 10.1111/pcmr.12498.Peer-Reviewed Original ResearchConceptsMouse melanoma cell lineMelanoma cell linesCell linesMouse cancer cell linesVariety of cancersCancer cell linesMouse melanoma linesImmune therapyTumor immunologyCancer immunologyHost miceMouse modelCancer modelMelanoma linesDriver mutationsGenetic alterationsCancer biologyImmunologyTherapyCancerMice